Ventyx Biosciences is a biopharmaceutical company that develops oral medicines for autoimmune and inflammatory disorders. It offers VTX958, an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor; TX002, an oral, selective Phase 2-ready sphingosine 1 phosphate receptor 1 (S1P1R) modulator for ulcerative colitis (UC) and differentiated NOD-like receptor protein 3 (NLRP3) inhibitors.